Abstract
Left Ventricular Hypertrophy is a multifactorial condition involving genetic and signaling pathways. Current recommendations for treating hypertensive LVH include ACE inhibitors, RAS and CCBs. Despite numerous drug therapies for ventricular hypertrophy, patients often deteriorate and experience a decline in ventricular function ultimately leading to heart failure. For this reason, alternative therapies must be investigated. Stem cells possess the potential to divide at a high capacity, self-renew and differentiate into numerous cardiac cell lineages. Furthermore, stem cells are connected to ventricular remodeling and are vital in maintaining the homeostasis of the heart. Further examination of the role of stem cells in LVH could result in the development of targeted therapeutic interventions for prevention or reversal of the phenomenon.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Regenerative Medicine & Biology Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
